Fresh analysis reveals that patients who stop using new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Findings released in a prominent health publication demonstrates that while overweight individuals can lose substantial amounts of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users using these medications should be cognizant of the danger of rapid rebound weight gain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
Such speed of regain means a return to original weight in about 18 months.
Weighing Approaches
The analysis, which examined dozens of studies involving thousands of patients, compared the effects of the injectable medications with other pills.
Researchers note that people who lose weight through dieting generally have a more gradual creep back—approximately 100 grams monthly—after stopping.
Understanding the Fast Rebound
Doctors propose the way of the drugs explains the accelerated weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, considering the high risk of weight regain, the therapy might need to be long-term.
This perspective is supported by pharmaceutical companies, who note that the results "highlight the long-term character of obesity," akin to managing conditions like diabetes.
User Experiences
Individuals who have stopped the jabs explain a sudden return of appetite.
"It felt as if a switch activating and you're instantly starving," said a patient.
This challenge is exacerbated if patients have not adopted permanent dietary or behavioural modifications during therapy.
Growing Use
Survey data suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Adoption is greater among women compared to males.
- The middle-aged age group shows the highest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while the jabs are effective agents for weight loss, they are not a standalone fix and long-term success relies on ongoing behavioural management.
